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a  b  s  t  r  a  c  t
Cell  culture  is now  available  as a method  for  the  production  of  inﬂuenza  vaccines  in addition  to eggs.
In  accordance  with  currently  accepted  practice,  viruses  recommended  as  candidates  for  vaccine  man-
ufacture  are isolated  and  propagated  exclusively  in  hens’  eggs  prior  to distribution  to manufacturers.
Candidate  vaccine  viruses  isolated  in cell culture  are  not  available  to support  vaccine  manufacturing  in
mammalian  cell  bioreactors  so egg-derived  viruses  have  to  be used.  Recently  inﬂuenza  A  (H3N2)  viruses
have  been  difﬁcult  to isolate  directly  in  eggs.  As mitigation  against  this  difﬁculty,  and  the  possibility  of
no  suitable  egg-isolated  candidate  viruses  being  available,  it is proposed  to consider  using mammalian
cell  lines  for  primary  isolation  of  inﬂuenza  viruses  as  candidates  for  vaccine  production  in egg  and  cell
platforms.
To  investigate  this  possibility,  we  tested  the  antigenic  stability  of viruses  isolated  and propagated  in  cell
lines  qualiﬁed  for  inﬂuenza  vaccine  manufacture  and  subsequently  investigated  antigen  yields  of  such
viruses  in  these  cell  lines  at pilot-scale.  Twenty  inﬂuenza  A  and  B-positive,  original  clinical  specimensntigenic stability
enetic  stability
were  inoculated  in  three  MDCK  cell  lines.  The  antigenicity  of  recovered  viruses  was tested  by hemagglu-
tination  inhibition  using  ferret  sera  against  contemporary  vaccine  viruses  and  the  amino  acid  sequences
of  the  hemagglutinin  and  neuraminidase  were  determined.  MDCK  cell  lines  proved  to  be  highly  sensitive
for  virus  isolation.  Compared  to the  virus  sequenced  from  the original  specimen,  viruses  passaged  three
times  in  the  MDCK  lines  showed  up to 2  amino  acid  changes  in the  hemagglutinin.  Antigenic  stability
was  also  established  by hemagglutination  inhibition  titers  comparable  to those  of  the corresponding
∗ Corresponding author Inﬂuenza Division, Centers for Diseases Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, Inﬂuenza
ivision, 1600 Clifton Road, Mailstop A-20, Atlanta, GA 30333, USA. Tel.: +1 404 639 4968; fax: +1 404 639 2350.
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264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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reference  virus.  Viruses  isolated  in  any  of  the  three  MDCK  lines  grew  reasonably  well  but  variably  in
three MDCK  cells  and  in  VERO  cells  at pilot-scale.  These  results  indicate  that  inﬂuenza  viruses  isolated  in
vaccine certiﬁed  cell  lines  may  well  qualify  for use  in vaccine  production.
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. Introduction
Vaccination is the cornerstone of the global public health strat-
gy to mitigate an eventual inﬂuenza pandemic. Rapid production
f vaccine to immunize billions of people in a short period of time
equires development of alternative manufacturing platforms, such
s large-scale animal cell culture bioreactors. In combination with
ther methods, cell-based manufacturing would augment vaccine
anufacturing capacity to respond to a pandemic [1]. MDCK and
ERO cell culture–derived inﬂuenza vaccines have received regula-
ory approval in some countries [2,3]. Inﬂuenza vaccines produced
n cell cultures have relied on candidate vaccine viruses devel-
ped by the WHO  GISRS laboratories for vaccine production in
mbryonated eggs [4]. Although these viruses are ideal for the tra-
itional method of vaccine production in eggs, the growth can be
uboptimal for production of vaccines in cell cultures [4]. A sustain-
ble supply of circulating inﬂuenza viruses isolated in cell cultures
hat meet regulatory requirements would be required to support
ell-based vaccine manufacturing. Critical information on the com-
arative performance of several regulatory requirement-compliant
ell lines for isolation of inﬂuenza viruses from clinical species for
ubsequent use as candidate vaccine viruses is not available. In
ddition, it would be important to determine whether isolation of
iruses in a given cell line could have a detrimental impact on anti-
en yields in different cell lines used by other manufacturers; i.e.
oes virus isolation in suspension select for variant viruses with
ower replication efﬁciently in adherent cells? This information
ould support the selection of a certiﬁed cell line to be used in
he WHO  Collaborating Centers for isolation of candidate viruses
or vaccine manufacturing. Given the variability of isolation rates
n embryonated eggs [4–6], isolation of inﬂuenza viruses in cell
ulture would greatly increase the number of vaccine candidate
iruses and, in some circumstances, accelerate development of
iruses for vaccine manufacturing in both cell-based and egg-based
latforms.
The continuous evolution of inﬂuenza viruses is monitored
y the WHO  Global Inﬂuenza Surveillance and Response Sys-
em (GISRS) [5,7–9]. One of the main roles of this network is to
rovide candidate viruses for the production of inﬂuenza vaccines.
accine viruses recommended by the World Health Organiza-
ion (WHO) are mainly isolated and propagated in embryonated
ens’ eggs or chicken embryonic kidney cells prior to distribution
o vaccine manufacturers. However, a number of contemporary
nﬂuenza viruses replicate poorly in eggs [4,6], and therefore many
aboratories replaced this substrate with partially characterized
ammalian cells for the primary isolation of inﬂuenza viruses from
linical specimens, although these isolates cannot then be used
or vaccine production as the cells are not usually qualiﬁed for
anufacturing purposes. In contrast, viruses isolated in vaccine-
ualiﬁed cell lines would be suitable as candidate vaccine viruses
s long as they are in compliance with all other regulatory require-
ents [6,10,11]. Evaluation, development, and validation of this
lternative strategy should therefore be undertaken [12–14]. Man-
facturers currently use Madin-Darby canine kidney (MDCK) cells
2,15,16] and African Green Monkey Kidney (VERO) cells [17–20] to
anufacture licensed inﬂuenza vaccines. In addition, CAP human
mniocyte [21] and PER.C6 cells derived from a human retinoblas-
oma [22,23] are being considered as growth substrate for inﬂuenza
iruses.Elsevier  Ltd.  This  is an open  access  article under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
To qualify for vaccine production, virus isolates must meet a
number of requirements. First, they must be exclusively propagated
in cell lines that meet regulatory requirements for vaccine produc-
tion [10,11]. Second, virus preparations must be free of adventitious
agents [10]. Third, antigenic and genetic properties of the viruses
must remain stable over several passages and viruses should grow
to accepted high titers in both eggs and the cell lines certiﬁed for
vaccine production [10,24,25]. Cell lines to be used for the primary
isolation of inﬂuenza viruses from clinical specimens and vaccine
production must be sensitive to both, inﬂuenza A and B viruses.
MDCK  cells have the potential to meet regulatory standards
for vaccine production, and they support the growth of inﬂuenza
viruses from original clinical specimens and after passage. It is
known that inﬂuenza viruses isolated and propagated in mam-
malian cells often remain genetically and antigenically closely
related to the virus present in clinical specimens [26–28]. Isola-
tion in embryonated hens’ eggs and also in cells can lead to amino
acid changes in the hemagglutinin, which can occasionally alter
antigenicity rendering the isolates unsuitable as candidate vaccine
viruses [29–31]. Cell culture isolates may  thus increase the num-
ber of viruses available for vaccine virus selection and regulatory
authorities are willing consider such viruses for the production of
inﬂuenza vaccines [24,32].
In the present study we  evaluated the performance of vaccine
manufacturing cell lines [12,14,15,17,33,34] for primary virus iso-
lation from clinical specimens and analyzed the antigenic stability
and antigen yields of resulting isolates in pilot-scale manufacturing
processes.
2. Materials and methods
2.1.  Experimental design
This  study was  designed to serve two  purposes. Cell lines used
by vaccine manufacturers were evaluated for their permissiveness
to isolate inﬂuenza viruses from clinical specimens. Genetic and
antigenic stability, as well as the growth-characteristics of the iso-
lates, were monitored in the homologous cell line and in those used
by other manufacturers. Fig. 1 shows the 4 main experimental steps
and the 3 critical performance parameters of this study.
2.2.  Clinical specimens
Twenty  inﬂuenza virus-positive respiratory samples from
patients with inﬂuenza-like illness were included. These samples
were collected in the USA or in Finland during the 2007–2008
and 2008–2009 inﬂuenza seasons. Four groups of ﬁve specimens
were selected to represent each of the seasonal inﬂuenza subtypes:
A(H1N1) viruses, A(H3N2) viruses, inﬂuenza B viruses representing
the Yamagata lineage and the Victoria lineage. Each original spec-
imen was  divided into 10 aliquots and stored at −80 ◦C until used
for further experiments.
2.3.  Cell lines, culture conditions, virus isolation, and pilot-scaleThree  different Madin-Darby canine kidney cell lines (MDCK-
1[14,15]; MDCK-2[12,14,33]; MDCK-3[33]) and one African green
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Clinical specimens
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hig. 1. Goals of the study. The sensitivity of vaccine-certiﬁed cell lines for the primar
f  inﬂuenza viruses propagated in vaccine-certiﬁed cell lines; virus yield in pilot sc
onkey cell line (VERO [17]) were used in the experiments.
he MDCK-1 and MDCK-2 as well as the VERO cell lines were
nchorage-dependent; whereas the MDCK-3 line was cultivated
n suspension. The three MDCK cell lines were used for primary
solation of inﬂuenza viruses from clinical specimens and for pilot-
cale virus production. The VERO cell line was used for small-scale
roduction experiments, one representative isolate from each of
he four virus groups (H1N1, H3N2, B-Victoria, B-Yamagata) was
sed. For production, MDCK-1 was grown on micro-carriers in
erum free medium to which a protease was added to facilitate
irus replication. Virus was harvested when cytopathic effect (CPE)
as observed in all cells. MDCK-2 were grown in T-225 ﬂasks
n a serum-free medium, virus growth was monitored by micro-
copic observation for CPE and by hemadsorption assay (HA).
DCK-3 grew as a single-cell suspension in disposable shake
asks in a serum-free medium supplemented with recombinant
ovine trypsin. VERO cells were grown on micro carriers in serum-
ree medium supplemented with trypsin. Virus from small-scale
roduction was harvested, clariﬁed, stabilized by addition of 5%
lycerol using a standard protocol, stored at ≤−60 ◦C, and shipped
o the CDC for viral antigen content determination.
.4. Nucleotide sequence analysis from clinical specimens and
irus  isolates
The  full-length open reading frame of the hemagglutinin (HA)
nd the neuraminidase (NA) genes were sequenced following
CR-ampliﬁcation as described [35]. Sequences were submitted to
enBank (accession numbers in supplementary Table S1).
.5.  Antigenic characterization by hemagglutination-inhibition
ssay
Antigenic characterization of the isolates was  achieved by
emagglutination inhibition assay (HI) according to a standardizedtion of inﬂuenza viruses from clinical specimens; the antigenic and genetic stability
duction platforms; antigen yield in pilot scale production platforms.
protocol,  using ferret antisera raised against a panel of cell-grown
reference viruses and either turkey or guinea pig red blood cells[36].
2.6. Viral antigen yield assessment
Viruses originally isolated in the 3 MDCK cell lines were then
propagated on a small-scale production platform by four vaccine
producers in their respective certiﬁed cell lines. Virus yield was
monitored by methods representative of those routinely used by
these producers for assessing virus production, i.e., hemaggluti-
nation; infectivity titration with a Tissue Culture Infectious Dose
50% endpoint (TCID50); infectivity titration by ﬂuorescent focus
forming unit (FFU); infectivity titration by ﬂuorescent infection
unit (FIU), respectively. A 22.5 mL  volume of pooled supernatants
from small-scale production batches was  layered on to 9 mL  of 30%
(w/w) sucrose on top of a cushion of 4.5 mL  55% (w/w) sucrose and
centrifuged at 90,000 × g for 14 h at 4 ◦C. Fractions were collected
from the top of the sucrose gradient and those with the highest
HA titers and protein concentration were pooled. The virus was
pelleted by ultracentrifugation at 100,000 × g for 2 h at 4 ◦C. Total
protein content in resuspended viral pellets was  determined by the
BCA method [37] and expressed as total viral protein (mg/100 mL)
for each cell harvest.
3.  Results
3.1. Virus isolation efﬁciency
For  primary virus isolation, an aliquot of the 20 clinical samples
was inoculated into the three MDCK cell lines and embryonated
hens’ eggs. In MDCK-2 and MDCK-3 cells all viruses grew after
one blind passage following primary inoculation (Table 1). All ﬁve
inﬂuenza A(H1N1) and B Victoria-lineage viruses but only 60%
of the B Yamagata-lineage viruses grew at the second passage in
MDCK-1 cells, whereas 60% of inﬂuenza A(H3N2) viruses grew on
the third passage. For comparison, isolation efﬁciency in eggs was
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Table 1
Isolation of seasonal inﬂuenza viruses in MDCK cell lines used in vaccine manufacturing.
Cell line Total number of
isolates  recovered
Inﬂuenza A(H1N1) Inﬂuenza A(H3N2) Inﬂuenza B Victoria-like Inﬂuenza B Yamagata-like
P1a P2b P1 P2 P1 P2 P1 P2
MDCK-1 16 1 4 0 1c 4 1 3 0
MDCK-2  20 0 5 0 5 0 5 0 5
MDCK-3  20 0 5 0 5 0 5 0 5
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pa Isolates recovered upon primary inoculation.
b Isolates recovered upon ﬁrst blind passage.
c Two additional inﬂuenza A(H3N2) isolates were obtained upon second blind pa
0% for inﬂuenza A(H1N1) and inﬂuenza B Victoria-lineage, 40%
or inﬂuenza A (H3N2), and 20% for inﬂuenza B Yamagata-lineage
t passage levels E3, E4, E3, and E3, respectively. The characteris-
ics of viruses isolated in embryonated hens’ eggs will be presented
lsewhere [38]. Overall, both anchorage dependent and suspension
DCK cells were more sensitive than eggs by at least an order of
agnitude for primary isolation of inﬂuenza A and B viruses.
.2.  Genetic stability of viruses during isolation and pilot-scale
ropagation
To  analyze the genetic stability of the HA and NA genes
fter sequential passages in each of the three MDCK lines their
equences were compared to those ampliﬁed directly from the
linical specimens. The number of amino acid changes observed
n the hemagglutinin of the viruses recovered after passage in the
espective cell lines are shown in Table 2. Compared to the virus
resent in the original specimen, viruses passaged three times in
he MDCK lines showed on average between 0 and 2.2 amino acid
hanges in the hemagglutinin, resembling changes noted by isola-
ion in eggs [26,28,39–44]. The number of amino acid changes in the
A were similar to those of observed in the HA (data not shown).
.3.  Antigenic stability of viruses propagated in different cell lines
After  three passages in each of the three MDCK cell lines, anti-
enic characteristics of the viruses were determined by HI test. HI
iters of tested viruses were compared with those obtained with
he reference virus, and the number of viruses with signiﬁcant
eduction of HI titers relative to homologous titers of the reference
iruses are shown in Table 3. HI titers obtained from the differ-
nt viruses with a given antiserum were within ≤4-fold of the
iter its homologous antigen, indicating that a majority of viruses
ropagated in any of the three cell lines were antigenically similar
o the reference viruses. However, ≥4-fold differences in HI titers
ere observed among several viruses isolated from MDCK cell lines.
nterestingly, most of the ≥4-fold HI titer differences were observed
mong the H3N2 viruses followed by H1N1 viruses. The majority of
nﬂuenza B viruses isolated from the three MDCK cell lines showed
I titer differences <4-fold relative to the homologous virus titers.
able 2
umulative amino acid mutations observed in the HA of viruses analyzed after 3
assages in the MDCK cell linesa.
Cell line A(H1N1) A(H3N2) B-Victoria B-Yamagata
MDCK-1 11 (1–4)b 6 (0–2) 9 (1–4) 5 (0–3)
MDCK-2 8 (0–3) 4 (0–3) 7 (0–3) 4 (2)
MDCK-3 2 (0–1) 11 (2–3) 5 (0–3) 0 (0)
Total number of mutations 15 15 15 9
Average mutations/virus 0.4–2.2 1–2.2 1–1.8 0–2
a Amino acid changes relative to the sequence from original clinical specimen.
b Range of amino acid substitutions identiﬁed per individual viruses..
3.4. Growth characteristics of viruses in small-scale production
experiments
To  determine growth-characteristics of viruses isolated in
MDCK-1, MDCK-2, and MDCK-3 cells, representative viruses were
further propagated on a small-scale scheme using the three MDCK
cell lines and the VERO cell line at the production facilities of the
holders of these cell lines. Growth characteristics were analyzed
by methods routinely used by these manufacturers when moni-
toring virus replication. Results from these experiments suggested
that inﬂuenza A and B viruses isolated in MDCK-1, MDCK-2, and
MDCK-3 cell lines replicated to acceptable levels in comparison to
levels routinely achieved by manufacturers in all four production
cell lines but the virus titers could vary more than 10-fold (Table 4).
Virus protein yield from small scale production platforms was
assessed after concentration and puriﬁcation of virus from cul-
ture supernatant (Fig. 2). The purity of the sucrose gradient
concentrated viruses from production cell lines MDCK-1 and
MDCK-3 was further veriﬁed by SDS-PAGE analysis. Protein con-
centration analysis suggested that MDCK-1 and MDCK-3 cell lines
produced higher antigen yields than the MDCK-2 and VERO cell line
except for the superior yield of H1N1 antigen in the VERO cell line.
These results indicate that different production cell lines may  have
variable yields of seasonal inﬂuenza viruses, mainly dependent on
differences of the cell density required for optimal bioreactor con-
ditions of the speciﬁc cell lines and therefore further adaptation
or optimization in individual cell lines may  be required for large-
scale production, although these changes may  alter the antigenic
properties.
4. Discussion
For the foreseeable future it is anticipated that the global supply
of inﬂuenza vaccine will be manufactured predominantly in eggs.
Vaccine production relies on a global network of public health, aca-
demic and industrial laboratories that work in concert to ensure
the rapid update of vaccine composition when antigenic variants
become dominant in the world [5]. The present study was designed
to evaluate the performance characteristics of several cell lines
which are already certiﬁed for or are currently being evaluated
by national regulatory authorities to determine their suitability for
human inﬂuenza vaccine manufacturing.
In general, MDCK cells appear to be the most permissive cell
line for isolation and propagation of human and animal inﬂuenza
viruses [45,46]. In the present study, the three MDCK cell lines used
for primary isolation of inﬂuenza A and B viruses from clinical spec-
imens proved to be highly sensitive. After one blind passage, all
20 isolates were detected in one of the two  anchorage-dependent
MDCK lines (MDCK-3) and in the suspension MDCK  line. The
anchorage-dependent MDCK-1 cells appeared to be slightly less
sensitive, as two  inﬂuenza A(H3N2) viruses and two inﬂuenza
B viruses of the Yamagata lineage remained undetected. Recent
inﬂuenza A(H3N2) may  not grow or require one or more blind
passages before the virus can be detected in culture. In this study
R.O. Donis / Vaccine 32 (2014) 6583–6590 6587
Fig. 2. Virus protein yield in pilot scale production platforms. One representative A(H1N1) and A(H3N2) virus and one virus representing each of the two  type B lineages
isolated in each of the three cell lines (MDCK-1: gray stipple ﬁll bar; MDCK-2: hatched ﬁll bar; and MDCK-3: black ﬁll bar) were propagated in four vaccine-certiﬁed cell lines
(indicated in the horizontal axis). Virus was  puriﬁed from 22.5 mL culture supernatant and the content of virus protein was determined. Values are means of two independent
p es am
c ish th
e
(
l
a
a
e
a
i
t
M
p
t
l
i
a
d
s
l
t
M
f
p
v
≤
v
suriﬁcations, with the standard error shown as T bar extensions. The large differenc
ell  densities relative to optimal bioreactor conditions and do not necessarily dimin
ggs achieved a 45% isolation rate overall and 40% and 20% for A
H3N2) and B-Yamagata viruses, respectively, however during the
ast decade, the proportion of H3N2 viruses that has been recover-
ble in eggs has declined to <1% in some laboratories [4,6,31,47]
nd therefore, viruses isolated in cell culture may  not grow in
ggs.
Sequence analysis of the isolated viruses revealed up to 4 amino
cid substitutions at 9 to 15 residues of the mature hemagglutinin
n comparison to the sequence of the original virus isolated from
he clinical sample. Importantly, several isolates from MDCK-2 and
DCK-3 were identical to the virus genomes in the original sam-
les. It was noted that some of the observed mutations resulted in
he loss or gain of potential glycosylation sites.
Comparing the cumulative number of mutations for viruses iso-
ated in each of the cell lines revealed that viruses propagated
n suspension-grown MDCK-3 cells showed the lowest number of
mino acid substitutions, followed by MDCK-2 and MDCK-1. These
ifferences were small and lacked statistical signiﬁcance. This
uggests that propagation of inﬂuenza viruses in these three MDCK
ines does not lead to major changes in the amino acid sequence of
he hemagglutinin.
The antigenic properties of viruses propagated in the three
DCK lines were determined by HI test using post-infection
erret antisera to reference or vaccine viruses used during the
eriod when the clinical specimens were collected. The majority of
iruses propagated in the three MDCK cell lines remained within
2-fold titer differences, suggesting that a high proportion of
iruses propagated in different MDCK cells lines are antigenically
imilar to the reference viruses and would merit characterizationong production cell lines are most likely the result of approximately 10-fold lower
eir acceptability for large-scale production of inﬂuenza vaccines.
by reciprocal HI testing. These results indicate that isolation and
passage of inﬂuenza viruses in the commonly used MDCK cell lines
can yield antigenically distinct viruses (HI titer differences of >4
fold) with low frequency.
As  soon as vaccine manufacturers adopt the use of cell
culture–isolated inﬂuenza viruses in vaccine production, one or
more of the approved cell lines could be made available to WHO  Col-
laborating Centers for the isolation of viruses from virus-positive
samples received from National Inﬂuenza Centers. These qualiﬁed
cell lines could provide an alternative to eggs in the event that
isolation of a suitable virus for vaccine production has not been
possible. Preliminary results from a follow-up studies show that
H3N2 viruses with high infectivity harvested from MDCK cultures
can be propagated in eggs. Results of egg based studies will be the
subject of a separate report.
To estimate the potential performance of viruses isolated in var-
ious cell lines in cell-based vaccine manufacturing, one inﬂuenza
A virus of each subtype and one inﬂuenza B virus of each lineage
isolated in each of the three MDCK cell lines was  grown in a small-
scale production experiment using the three MDCK and the VERO
cell lines at the corresponding vaccine manufacturing sites. Infec-
tivity titers in cell culture supernatants were determined using
different methods at each manufacturing plant, which makes quan-
titative comparisons unfeasible. However, antigen amounts as well
as infectivity titers did not vary signiﬁcantly in the different com-
binations of isolation and production cell lines. It is thus likely that
viruses isolated in certiﬁed cell lines by WHO  Collaborating Centers
can be successfully propagated in any of the cell lines currently used
by different vaccine producers.
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Table 3
Antigenic characterization of inﬂuenza viruses propagated in three different MDCK cell lines.
Cell line HI  titer reductionb Ferret antiserum toa
Inﬂuenza A(H1N1) Inﬂuenza A(H3N2) Inﬂuenza B Yamagata lineage Inﬂuenza B Victoria lineage
Brisbane/59/2007 Hong Kong/1870/2008 Brisbane/10/2007 Perth/16/2009 Florida/4/2006 Bangladesh/3333/2007 Brisbane/60/2008 Texas/26/2008
MDCK-
1
0-fold 1(5)c 2(3) 2(3) 3(3) 3(3)
2-fold 4(5) 1(5) 2(5) 1(5)
4-fold  4(5) 1(3) 3(5) 4(5)
>8-fold 1(3)
MDCK-
2
0-fold 1(2) 1(2) 1(2) 2(2) 3(5)
2-fold  1(2) 1(2) 2(5) 2(5)
4-fold  1(2) 3(5)
≥8-fold 1(2) 1(2) 2(2)
MDCK-
3
0-fold  4(5) 3(5) 3(5) 3(5)
2-fold  5(5) 5(5) 1(5) 2(5) 5(5) 2(5)
4-fold  1(5)
>8-fold 1(5)
a HI titers of tested viruses were compared with results obtained for the homologous reference viruses.
b Number of viruses with x-fold reduction to homologous titers of the reference viruses listed.
c Number of viruses tested in parenthesis.
Table 4
Virus  yield of 4 representative viruses of the two inﬂuenza A subtypes and the two  inﬂuenza B lineages.
Cell line original virus
isolation
Virus  type,
subtype
Virus
identiﬁcation
Cell line used for virus production
MDCK-1 MDCK-2 MDCK-3 VERO-1
Infectivity HA
(HPLC  U/mL) Run 1
Infectivity HA
(HPLC  U/mL) Run 2
Infectivity  titer
Log10 FFUa/mL
HAb titer
HAUc/100uL
Infectivity titer
Log10 FIUd/mL
HA  titer
HAU/50 L
Infectivity  titer
log10 TCID50e/mL
MDCK-1 A(H1N1) A/Texas/89/2009 13.3 12.5 5.6 1024 7.5 1024 7.8
A(H3N2)  A/Finland/97/2009 7.6 7.4 6.9 512 7.5 128 7.2
B/Vicf B/Texas/23/2009 19.7 16.3 5.7 1024 6.6 128 6.5
B/Yamag B/Finland/214/2008 20.4 23.9 7.2 2048 8.0 256 7.3
MDCK-2 A(H1N1)  A/Texas/89/2009 21.2 No full CPE 8.6 2048 7.8 256 7.5
A(H3N2)  A/Finland/97/2009 11.9 15.1 7.3 256 6.8 512 7.5
B/Vic  B/Texas/23/2009 18.3 21.0 6.8 512 7.2 128 6.7
B/Yama  B/Finland/214/2008 26.4 22.8 6.9 2048 7.1 256 7.4
MDCK-3 A(H1N1)  A/Texas/89/2009 18.8 11.5 8.8 2048 7.6 1024 8.4
A(H3N2)  A/Finland/97/2009 17.0 11.4 7.7 256 7.6 64 7.4
B/Vic  B/Texas/23/2009 24.7 21.4 8.1 1024 7.0 32 4.8
B/Yama  B/Finland/214/2008 17.6 14.3 8.4 ± 0.04 2048 7.1 512 6.3
a FFU: ﬂuorescent focus unit.
b HA: hemagglutination.
c HAU: hemagglutination units.
d FIU: ﬂuorescent infection focus unit.
e TCID50: tissue culture infectious dose 50%.
f Vic: Victoria-like.
g Yama: Yamagata-like.
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Virus protein yields were determined after concentration and
uriﬁcation of virus from small-scale production. In these exper-
ments the MDCK-2 cell line, in accordance to routine production
rocedures at this manufacturing plant, was used at one order of
agnitude lower cell density than the other cell lines. As a conse-
uence, protein yields from this cell line were approximately 2 to 10
imes lower than those observed from the other cell lines. Protein
ields from the other two MDCK cell lines did not differ signiﬁcantly
rom each other. For the inﬂuenza A(H1N1) virus, the highest pro-
ein yields were obtained with the VERO cell line. However, with
nﬂuenza A(H3N2) and inﬂuenza B viruses of both lineages, protein
ields from the VERO cell line were 1.5 to 10-fold lower than those
btained with the MDCK-1 and MDCK-3 cell lines.
These experiments were designed as a proof of concept that
nﬂuenza viruses isolated in cell cultures could be successfully
sed for production of inﬂuenza vaccines in certiﬁed mammalian
ell lines selected by vaccine manufacturers. The MDCK cell lines
roved to be sensitive for primary isolation of inﬂuenza A and B
iruses. The viruses studied retained their genetic and antigenic
roperties well during propagation in the cell lines. Antigen and
rotein yields were comparable in all different combinations of cell
ines for primary isolation and for production. The scarcity of pos-
tive clinical specimens with a sufﬁciently high virus titer and/or
olume to allow for performance of all the experiments limited
he total number of isolates tested. However, inﬂuenza viruses iso-
ated in certiﬁed cell lines fulﬁlled all of the requirements needed
or acceptable vaccine seed viruses. Although the A(H1N1) sea-
onal viruses used in the present study have been replaced by the
(H1N1)pdm09 viruses since the 2009 pandemic, these results may
e applicable to the new lineage as well. The feasibility of inﬂuenza
iruses isolated in certiﬁed cell lines for use in egg-based produc-
ion platform is currently under evaluation and those results will
e presented elsewhere.
Isolation  of recent inﬂuenza A (H3N2) viruses is becoming
ncreasingly difﬁcult in eggs, which severely limits the number of
vailable virus candidates that could be evaluated for vaccine pro-
uction. Alternative strategies must therefore be designed, tested,
nd evaluated including the use of viruses isolated in approved
ell lines for further propagation in both cell-based and egg-based
nﬂuenza vaccine manufacturing. The promising results obtained
n the present study may  assist decision making by public health
aboratories, regulatory agencies and industry regarding the gen-
ration of virus isolates for cell-based manufacturing of inﬂuenza
accines
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